AMC Bio, incorporated in Strasbourg, France, harnesses untapped potential of microbial proteins and peptides to address unmet patient needs. AMC Bio is focusing initial efforts on development and commercialization of antiviral therapies using one of 4000 Mycobacterium tuberculosis proteins, MPT63, revealing the activity of the protein and its derived peptides on RNA viruses including first-in-class therapy for Dengue and Long COVID.

Just as antibiotic discovery from soil microbes revolutionized treatment of bacterial infections in the 20th century, microbially derived peptides offer breakthrough broad-spectrum therapies and cures for the 21st century.

Contact Us: [email protected]